基线与早期[18F]FDG PET/CT代谢参数作为晚期皮肤BRAFV600突变黑色素瘤BRAF/MEK抑制剂耐药预测生物标志物
多中心试验纳入75例晚期BRAF突变黑色素瘤患者,接受维莫非尼/考比替尼治疗,于基线、第2周和第7周行[18F]FDG PET/CT。基线MTV是PFS最强预测因子(AUCT=6个月=0.714),MTV高于最佳截断值45.3 mL与进展/死亡风险增加相关(HR=2.97,95%CI 1.17-7.52,P=0.022)。第7周ΔSUVpeak%低于64%者进展风险增加三倍以上,PFS为5.0个月 vs 14.7个月(P=0.0002)。
要点
- 基线MTV是晚期BRAF突变黑色素瘤BRAF/MEK抑制剂治疗PFS的最强预测因子(AUCT=6个月=0.714)。
- MTV高于最佳截断值45.3 mL与进展/死亡风险增加相关(HR=2.97,95%CI 1.17-7.52,P=0.022)。
- 第7周ΔSUVpeak%低于64%者进展风险增加三倍以上,PFS为5.0个月 vs 14.7个月(P=0.0002)。
核心结论
- 本研究支持MTV和TLG作为晚期黑色素瘤BRAF/MEK抑制剂治疗PFS的稳健预测标志物。
- 监测早期PET参数变化可为了解治疗反应和疾病进展提供有价值的信息。
研究设计与样本
- 多中心试验纳入75例转移性黑色素瘤患者,接受维莫非尼/考比替尼治疗。
- 于基线、第2周和第7周行[18F]FDG PET/CT扫描,分析汇总转移灶的SUVpeak、MTV和TLG及其随时间的变化百分比(∆)。
- 试验注册号Clinicaltrials.gov NCT02414750,2015年4月10日回顾性注册。
主要发现
- 基线PET参数中位数:SUVpeak 12.59(范围3.13-50.59),MTV 159 mL(范围0-1897 mL),TLG 1013(范围1-13162)。
- 基线MTV是最强预测因子(AUCT=6个月=0.714),而MTV、TLG的早期变化以及尤其是第7周ΔSUVpeak%表现出相似或更好的预测性能(P=0.017 vs 基线SUVpeak)。
- TLG低于中位数的患者PFS显著延长(15.4 vs 8.5个月,P=0.024)。
- MTV高于最佳截断值45.3 mL与进展/死亡风险增加相关,即使校正LDH、ECOG状态和转移部位后仍显著(HR=2.97,95%CI 1.17-7.52,P=0.022)。
- 第2周ΔSUVpeak%在多变量分析中无预测价值,但第7周变得有预测价值(中位ΔSUVpeak%:64),ΔSUVpeak%低于64%者进展风险增加三倍以上(P=0.0014);PFS在低于中位数者为5.0个月(95%CI 4.3-NA),高于中位数或扫描不可量化者为14.7个月(95%CI 9.2-20.2)(P=0.0002)。
临床怎么用
- 作者认为MTV和TLG可作为晚期黑色素瘤BRAF/MEK抑制剂治疗PFS的稳健预测标志物。
- 作者认为监测早期PET参数变化可为了解治疗反应和疾病进展提供有价值的信息。
局限性
- 试验为回顾性注册(2015年4月10日回顾性注册)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: [18F]FDG PET/CT plays a crucial role in evaluating cancer patients and assessing treatment response, including in BRAF-mutated melanoma. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) have emerged as promising alternatives to standardized uptake value (SUV)-based measures for tumor assessment. This study evaluates the predictive value of SUVpeak, MTV, and TLG in predicting progression-free survival (PFS) in advanced BRAF-mutated melanoma treated with BRAF/MEK inhibitors. RESULTS: Seventy-five patients with metastatic melanoma were enrolled in a multi-center trial and treated with vemurafenib/cobimetinib. [18F]FDG-PET/CT scans were performed at baseline, week-2, and week-7. Imaging analysis included SUVpeak, MTV, and TLG of summed metastases, as well as percentage changes over time (∆). Baseline median PET-parameters were SUVpeak 12.59 (range 3.13-50.59), MTV 159mL (range 0-1897 mL), and TLG 1013 (range 1-13162). Baseline MTV was the strongest predictor (AUCT=6 months=0.714), while early changes in MTV, TLG, and especially week-7 ΔSUVpeak% showed similar or improved performance (P = 0.017 vs. baseline SUVpeak). Patients with TLG below the median had significantly prolonged PFS (15.4 vs. 8.5 months, P = 0.024). MTV above optimal cutoff (45.3 mL) was associated with an increased risk of progression/death, even after adjusting for LDH, ECOG status, and metastatic sites (HR = 2.97, 95% CI 1.17-7.52, P = 0.022). At week-2, ∆SUVpeak% was not predictive in a multivariable analysis, but became predictive at week-7 (median ∆SUVpeak%: 64), with a more than three-fold hazard of progression for patients with ∆SUVpeak% below 64% (P = 0.0014); PFS was 5.0 months (95% CI: 4.3-NA) for patients below the median versus 14.7 months (95% CI: 9.2-20.2) for those above or with non-quantifiable scans (P = 0.0002). Median ∆MTV was 95.5% at week-2 and 97.6% at week-7, with significant PFS differences at both time points (week-2: P = 0.020, week-7: P < 0.001). As expected, TLG mirrored MTV. Patients with MTV increases at week-7 after an initial response at week-2 had a median PFS of 5.3 vs. 12.6 months for those with stable or declining MTV (P = 0.0023). Intra-patient metabolic heterogeneity was also associated with outcome, with early reductions in SUVpeak variation between lesions correlating with better PFS. CONCLUSION: This study supports the use of MTV and TLG as robust predictive markers for PFS in advanced melanoma treated with BRAF/MEK-inhibitors. Monitoring early PET parameters changes can provide valuable insights into therapeutic response and disease progression. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02414750. Registered 10 April 2015, retrospectively registered.
引用
- van der Hiel B, de Wit-van der Veen BJ, van den Eertwegh AJM, et al. Metabolic parameters on baseline and early [18F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma. EJNMMI Res. 2025. PMID: 40434500. doi:10.1186/s13550-025-01259-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。